Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease

Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2014-07, Vol.10 (3), p.752
Main Authors: Bhamare, Sulabhchandra, Prabhakar, Pimparkar, Dharmadhikari, Aniruddha, Dedeepiya, Vidyasagar Devaprasad, Terunuma, Hiroshi, Senthilkumar, Rajappa, Srinivasan, Thangavelu, Reena, Helen C, Preethy, Senthilkumar, Abraham, Samuel J K
Format: Article
Language:English
Subjects:
Adoptive Transfer
Bladder cancer
Care and treatment
Case studies
Combined Modality Therapy
Diagnosis
Female
Gallbladder cancer
Gallbladder Neoplasms - diagnosis
Gallbladder Neoplasms - immunology
Gallbladder Neoplasms - pathology
Gallbladder Neoplasms - therapy
Humans
Immunotherapy
Killer Cells, Natural - immunology
Methods
Middle Aged
T-Lymphocytes - immunology
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.
ISSN:0973-1482
1998-4138
DOI:10.4103/0973-1482.136048